Abstract Number: 1365 • ACR Convergence 2022
Adverse Events Associated with Belimumab Use in Pediatric Patients: Review and Analyses of the FDA Adverse Event Reporting System Database
Background/Purpose: FDA approved belimumab, the first targeted biological treatment for SLE, in March 2011 for adults with active, seropositive SLE receiving standard therapy. The indicated…Abstract Number: 1821 • ACR Convergence 2022
Colchicine and Other Gout Medications and the Risk of COVID-19 Infection, Hospitalization, and Subsequent Outcomes in People with Gout
Background/Purpose: To examine whether the use of colchicine and other gout medications is associated with the risk of COVID-19 infection, hospitalization, and subsequent outcomes in…Abstract Number: 0781 • ACR Convergence 2022
Rituximab Treated Patients with Hypogammaglobulinemia Are Less Likely to Seroconvert Following SARS-CoV-2 Vaccine Supplemental Dose
Background/Purpose: Rituximab (RTX) is a very effective treatment for autoimmune rheumatic diseases (AIRD). However, treatment increases risk of infections and impairs responses to vaccines. Prior…Abstract Number: 1396 • ACR Convergence 2022
Risk of Hospitalized Infections in Older Elderly Rheumatoid Arthritis Patients Treated with Biological/Targeted Synthetic DMARDs: Evaluation Using Data from a Japanese Claims Database
Background/Purpose: Safety evidence of biological or targeted synthetic DMARDs (b/tsDMARDs) is still insufficient in older elderly ( >=75 years old (y/o)) patients with rheumatoid arthritis…Abstract Number: 1864 • ACR Convergence 2022
Hepatitis B Exposure and Infection in Idiopathic Inflammatory Myopathies: Prevalence, Presentation, and Treatment Response
Background/Purpose: Hepatitis B (HBV) screening in patients with autoimmune conditions is vital prior to the initiation of immunosuppressive therapy given the risk of HBV reactivation.…Abstract Number: 0120 • ACR Convergence 2022
Epstein Barr Virus Reactivation in Native American Rheumatic Disease Patients Is Associated with Systemic Disease and Rheumatoid Arthritis but Not Other Rheumatic Diseases
Background/Purpose: EBV infection is associated with autoantibody development in the preclinical period of rheumatic diseases, such as SLE and RA. Furthermore, EBV reactivation, characterized by…Abstract Number: 0784 • ACR Convergence 2022
Breakthrough SARS-CoV-2 Infections in Immune Mediated Disease Patients Undergoing B Cell Depleting Therapy: A Retrospective Cohort Analysis
Background/Purpose: Immunocompromised patients with immune mediated inflammatory diseases (IMIDs) undergoing therapy with B cell depleting agents (BCDT) are among the most vulnerable to severe COVID-19…Abstract Number: 1403 • ACR Convergence 2022
Herpes Zoster in Rheumatoid Arthritis: Prospective Single University Center Study
Background/Purpose: Patients with Rheumatoid arthritis (RA) have an increased risk of infections due to the disease itself, and/or immunosuppressive therapy. The risk of herpes zoster…Abstract Number: 1950 • ACR Convergence 2022
Morbidities Associated with Serious Infections in Patients with Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for serious infections. Several infection risk scores have been developed over the last decade for…Abstract Number: 0151 • ACR Convergence 2022
Novel Innate Immunity Predictors of Infections in Idiopathic Inflammatory Myopathies Patients: A Cohort Study
Background/Purpose: Risk factors associated with the development of infections in patients with idiopathic inflammatory myopathies (IIM) have not been fully addressed, particularly those related to…Abstract Number: 0785 • ACR Convergence 2022
Humoral Immune Responses Following Four SARS-CoV-2 Vaccine Doses or COVID-19 Infection in Patients with Immune-Mediated Inflammatory Diseases on Immunosuppressive Therapy: A Prospective Cohort Study
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy have impaired humoral immune responses to SARS-CoV-2 vaccination. This study aimed to assess serologic response…Abstract Number: 1422 • ACR Convergence 2022
Incidence and Determinants of Infection in Rheumatoid Arthritis (RA) Patients (Pts) Treated with Subcutaneous Golimumab (GLM) in Canadian Real-World Practice
Background/Purpose: Although biologic use in RA has a well-characterized infections risk factor, most studies were done on 1st-generation anti-tumor necrosis factor (TNFi) drugs or post-drug…Abstract Number: 1958 • ACR Convergence 2022
The Increased Risk of Staphylococcus Aureus Bacteremia in Rheumatoid Arthritis – What Is the Impact of Glucocorticoids, Biologic Disease-Modifying Anti-Rheumatic Drugs and Disease Activity: A Danish Nationwide Nested Case-Control Study in the DANBIO Registry
Background/Purpose: Staphylococcus aureus bacteremia (SAB) has high mortality.[1] We have previously identified an approximately doubled risk in patients with rheumatoid arthritis (RA),[2] but the role…Abstract Number: 0177 • ACR Convergence 2022
COVID-19 Vaccination-related Short-term Adverse Events in Patients with Idiopathic Inflammatory Myositis and Autoimmune Multimorbidity: Results from the COVID-19 Vaccination in Autoimmune Diseases Survey
Background/Purpose: COVID-19 vaccines are safe and effective, though patients with rare rheumatic diseases like idiopathic inflammatory myositis (IIMs), and those with multiple comorbidities continue to…Abstract Number: 0798 • ACR Convergence 2022
Uncovering the Relationship Between COVID-19 Outcome Severity and Rheumatic Disease
Background/Purpose: The COVID-19 pandemic has caused great concern amongst immunocompromised patients, especially those with rheumatic diagnoses. While much has been learned in the past two…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 36
- Next Page »
